Research Profile for Kalofonos Haralambos


«Return to previous page
General
Division of Medical Oncology, University Hospital
Department of Medicine
Research Activity
Molecular, laboratory and clinical oncology, colon adenocarcinoma, cancer biomarkers, translational research in oncology
Among the scientific interests of the Division of Medical Oncology are the diagnosis, therapy and support of patients suffering from cancer as well as aspects of clinical and translational research in oncology. The group evaluates potential biomarkers at the level of gene and protein expression. In addition the group analyzes gene poly-morphisms for preventive and prognostic purposes, in association with high risk population groups for cancer development, drug efficacy, response in chemotherapy and targeted therapeutic protocols. In colon adenocarcinoma, the team studies the gene and protein expression pattern of a number of genes, i.e. EGFR, HER-2, HER-3, COX-2, ERCC1, Parvins A and B, TGF-β inhibitors i.e. SnoN and Ski, Survinin, POLR2F, ATP6V0A1, PRNP, NFY-C and RORA and gene polymorphisms (Survivin -31, arkd (arkadia), SCN2A, ITGB3, PRN, endothylin-1 and EdnRA) for prognostic purposes or toxicity biomarkers related to various therapies. In non-microcellular lung carcinoma, the group analyzes NFκ-B2 protein levels and gene polymorphisms for prognostic purposes
Research Infrastructure
Prof. Haralabos Kalofonos

Other faculty members of the Division of Medical Oncology
Drs Koutras A., Makatsoris Th., Onyenadum A., Antonakopoulou A., Giannopoulou A., Ifanti A., Iconomou Gr., Argyriou A., Kyriakopoulou R., Bouboukas G., Peroukidis S.

Laboratory of Clinical Oncology
Research Activities
• Evaluation of potential biomarkers at the level of gene and protein expression
• Gene polymorphisms for preventive and prognostic purposes associated with high risk population groups for cancer development, drug efficacy, response in chemotherapy and targeted therapeutic protocols
Kalofonos H.P., Sivolapenko G., Courtenay-Luck N., Snook D.E., Hooker G.R., Winter R., McKenzie C.G., Taylor-Papadimitriou J., Lavender P.J. and Epenetos A.A. Antibody guided targeting of non-small cell lung cancer using 111In-labelled HMFG1 F(ab’)2 fragments. Cancer Res., 48: 1977-1984, 1988.
2. Kalofonos H.P., Rowlinson G., Epenetos A.A. Enhancement of monoclonal antibody uptake in human colon tumour xenografts following irradiation. Cancer Res., 50: 159-163, 1990
3. Kalofonos H.P., Kosmas C., Hird V., Snook D.E., Epenetos A.A. Targeting of tumours with murine and reshaped human monoclonal antibodies against placental alkaline phosphatase: Immunolocalisation, pharmacokinetics and immune response. Eur J Cancer, 30: 1842-1850, 1994.
4. Karamouzis M.V., Likaki-Karatza E., Ravazoula P., Badra FA., Koukouras D., Tzorakoleftherakis E., Papavassilou A.G., Kalofonos HP. Non-palpable breast carcinomas: Correlation of mammographically detected malignant-appearing microcalcifications and molecular prognostic factors. Int J Cancer 102: 86-90, 2002.
5. Kalofonos HP, Aravantinos G, Kosmidis P, Papakostas P, Economopoulos T, Dimopoulos M, Skarlos D, Bamias A, Pectasides D, Chalkidou S, Karina M, Koutras A, Samantas E, Bacoyiannis C, Samelis GF, Basdanis G, Kalfarentzos F, Fountzilas G. Irinotecan or oxaliplatin combined with leucovorin and 5-fluorouracil as first-line treatment in advanced colorectal cancer: a multicenter, randomized, phase II study. Ann Oncol., 16(6):869-77, 2005.
6. Badra FA, Karamouzis MV, Ravazoula P, Likaki-Karatza E, Tzorakoleftherakis E, Koukouras D, Iconomou G, Xiros N, Siablis D, Papavassiliou AG, Kalofonos HP. Non-palpable breast carcinomas: Correlation of mammographically detected malignant-appearing microcalcifications and epidermal growth factor receptor (EGFR) family expression. Cancer Lett. 28;244(1):34-41, 2006.
7. Kalofonos H, Grivas P. Monoclonal antibodies in the Management of Solid Tumors. Current Topics in Medicinal Chemistry, 6: 1687-1705, 2006.
8. Kosmas C, Tsavaris N, Syrigos K, Koutras A, Tsakonas G, Makatsoris T, Mylonakis N, Karabelis A, Stathopoulos GP, Kalofonos HP. A phase I-II study of bi-weekly gemcitabine and irinotecan as second-line chemotherapy in non-small cell lung cancer after prior taxane + platinum-based regimens. Cancer Chemother Pharmacol. Cancer Chemother Pharmacol. 59(1):51-9, 2007.
9. Grivas PD, Antonacopoulou A, Tzelepi V, Sotiropoulou-Bonikou G, Kefalopoulou Z, Papavassiliou
AG, Kalofonos H. HER-3 in colorectal tumourigenesis: from mRNA levels through protein
status to clinicopathologic relationships. Eur J Cancer 43(17):2602-11, 2007.
10. Kosmidis PA, Kalofonos HP, Christodoulou C, Syrigos K, Makatsoris T, Skarlos D, Bakogiannis C, Nicolaides C, Bafaloukos D, Bamias A, Samantas E, Xiros N, Boukovinas I, Fountzilas G, Dimopoulos MA. Paclitaxel and gemcitabine versus carboplatin and gemcitabine in patients with advanced non-small-cell lung cancer. A phase III study of the Hellenic Cooperative Oncology Group. Ann Oncol 19:115-22, 2008.
11. Antonacopoulou A, Tsamandas AC, Petsas T, Liava A Scopa CD, Papavassiliou AG, Kalofonos HP. EGFR, HER-2 and COX-2 levels in colorectal cancer. Histopathology 53, 698-706, 2008.
12. Argyriou AA, Iconomou G, Kalofonos HP. Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature. Blood, 112 (5) 1593-9, 2008.
Indicatively: Medical Research Council, Hammersith Hospital, London UK, U. of Athens, Hellenic Cooperative Oncology Group, U. of Ioannina, Arist. U. of Thessaloniki, various Research Groups, Clinics, Laboratories and Departments of the U. of Patras
Additional Information